PCOS New Name: Why PCOS Was Renamed PMOS (2026 Guide)
In May 2026, PCOS (polycystic ovary syndrome) was officially renamed PMOS (polyendocrine metabolic ovarian syndrome) by a global consensus paper published in The Lancet and endorsed by the Endocrine Society. The rename emerged from an 11-year, 22,000-person international consensus — 86% of patients and 71% of clinicians supported the change. Nothing clinical changed: the Rotterdam diagnostic criteria, the treatment framework, existing diagnoses, prescriptions, and provincial billing codes are all identical. The new name corrects a decades-old inaccuracy — "polycystic ovary syndrome" overemphasized ovarian cysts (which are not true cysts) and obscured the condition's central features: insulin resistance, androgen excess, and cardiometabolic risk. "Polyendocrine metabolic ovarian" accurately names all three. For Canadian patients: your PCOS diagnosis remains valid as PMOS with no retesting required. For the full condition primer, see what is PCOS. For treatment under the new name, see PCOS treatment in Canada.
What changed in May 2026
PCOS was officially renamed PMOS in May 2026 — and if you have a PCOS diagnosis, your existing tests, treatments, and prescriptions are all unchanged. On May 12, 2026, The Lancet published a global consensus paper renaming polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). The Endocrine Society endorsed the change at publication, calling it a long-overdue correction to a name that had created confusion and contributed to underdiagnosis for decades.
The rename was not a small editorial decision. It is the product of an 11-year, multistep international consensus process that surveyed roughly 22,000 patients and clinicians across multiple countries. Eighty-six percent of the patients surveyed and seventy-one percent of the healthcare professionals supported adopting a new symptom-based and biologically accurate name in place of "polycystic ovary syndrome."
If you have PCOS — or have been told you might — this article explains exactly what changed, what didn't, and what it means for Canadian patients in practical terms. If you want a full primer on the underlying condition, see our Canadian guide to PCOS, which remains accurate in every clinical detail under the new name.
Take the free 3-minute quiz
What PMOS actually stands for
The full term — polyendocrine metabolic ovarian syndrome — is built to put the condition's three core features into the name itself:
- Polyendocrine — multiple interacting hormonal systems are involved, not one. Insulin, androgens (testosterone and related), and neuroendocrine hormones from the hypothalamic-pituitary axis all contribute. The condition is endocrine in the proper, system-spanning sense — not just gynecological.
- Metabolic — insulin resistance is a central and near-universal feature, present in an estimated 65–95% of patients regardless of body weight. Long-term type 2 diabetes risk, dyslipidemia, fatty liver, and cardiovascular disease are tied directly to this metabolic axis.
- Ovarian — the reproductive and ovulatory features (irregular periods, anovulatory infertility, characteristic ultrasound morphology) remain part of the picture. The ovaries are still where androgen overproduction originates and where the cycle disruption is observed.
Compare that to the old name. "Polycystic ovary syndrome" emphasized the ovarian-morphology finding — the small follicles visible on ultrasound — and led generations of clinicians and patients to think of the condition as fundamentally a problem with the ovaries. It is not. The ovarian features are one expression of a multi-system endocrine and metabolic syndrome, and the rename is meant to make that visible at the level of the label.
PMOS vs PCOS: is there a difference?
No — PMOS and PCOS are the same condition. The difference between PMOS and PCOS is the name and the emphasis it carries, not the medicine:
- Same diagnosis. The diagnostic criteria did not change with the rename. An existing PCOS diagnosis is a PMOS diagnosis; no re-testing is needed.
- Same management. Guideline-based care — lifestyle first, behavioural support, clinical options where appropriate — applies identically under both names. See PCOS treatment in Canada.
- Different emphasis. "Polyendocrine metabolic" foregrounds the hormone-system and metabolic drivers that "polycystic" hid. Clinically, that nudges care toward metabolic screening — the direction the 2023 international guideline was already pointing.
During the transition you will see both terms used interchangeably in Canadian clinics, lab requisitions, and insurance paperwork. That is expected and does not affect your care.
Why the rename happened
The Lancet consensus paper is explicit about what was wrong with the old name. The previous term was described as "inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing."
Four problems, in plain terms:
- It implied cysts that aren't really there. The small follicles seen on ultrasound are not cysts in the harmful sense — they are immature follicles arrested at an early stage of development. The name suggested a pathology that simply does not match the underlying biology, and many patients carried unnecessary worry about "ovarian cysts" for years.
- It hid the metabolic story. Insulin resistance is arguably the most clinically important feature of the condition for long-term health. The old name said nothing about it, and as a result many family-medicine encounters focused on cycle regulation and missed the cardiometabolic screening the 2023 international guideline recommends.
- It delayed diagnosis. Because the name pointed at the ovaries, women whose dominant symptoms were metabolic (weight changes, insulin resistance, fatigue) were often not recognized as PCOS cases at all, especially if their cycles were broadly regular or their ultrasound looked unremarkable.
- It curtailed research and policy. A name that frames a condition as gynecological tends to keep funding and policy attention inside gynecology. The rename is partly an attempt to bring PMOS into the endocrinology, metabolic-health, and cardiovascular-prevention conversations where its long-term risks actually sit.
The STAT News coverage of the rename frames it as the largest rename of a common condition in modern medicine, affecting an estimated 170 million people worldwide — roughly the population of Russia and Canada combined. The American Journal of Managed Care's coverage emphasizes the metabolic-recognition angle specifically.
What did not change
This part matters more than the rename itself for most patients. Everything clinical about the condition is the same:
- Diagnostic criteria. The Rotterdam criteria — two of three features (hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology) after excluding other causes — continue to apply unchanged. No new tests, no new thresholds.
- Treatment framework. The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS remains the operative treatment document. Lifestyle as the foundation, combined hormonal contraception for cycle and androgen management where appropriate, an insulin-sensitizing medication for insulin sensitization, targeted fertility care, and long-term cardiometabolic monitoring — all unchanged.
- Existing diagnoses. If you have a PCOS diagnosis on your chart, you have PMOS under the new name. No retesting, no requalification, no change to your medical record's clinical validity.
- Medications and prescriptions. Combined hormonal contraception, insulin-sensitizing medication, medications that reduce androgen activity, and fertility medications are all prescribed identically. Provincial drug benefits, private insurance coverage, and Health Spending Account eligibility are unaffected.
- Long-term risk profile. The elevated risks of type 2 diabetes, gestational diabetes, dyslipidemia, hypertension, non-alcoholic fatty liver disease, endometrial hyperplasia, and cardiovascular disease are documented under PMOS as they were under PCOS. The Diabetes Canada Clinical Practice Guidelines continue to recommend periodic screening.
In short: the science, the diagnosis, the treatment, and your existing care are unchanged. The label is what was updated.
See if Cloudcure is right for you
What this means for Canadian patients
A few practical points specific to the Canadian context:
Your family physician may be using either term. Adoption in clinical practice is uneven during a rename of this scale. Some Canadian physicians have already moved their language and chart notes to PMOS; others continue using PCOS; many use both interchangeably during the transition. None of this affects the quality of your care. If your physician is still using PCOS, that is a normal early-rollout pattern, not an oversight.
SOGC adoption is in progress. The Society of Obstetricians and Gynaecologists of Canada — the body that anchors Canadian clinical practice in this space — issued an acknowledgement of the rename at the time of Lancet publication and is updating its patient-facing materials and position statements through 2026. The clinical content of those documents will not change; only the terminology.
Provincial billing codes will lag. Diagnostic codes for PCOS remain in active use across all Canadian provinces and territories. They will be mapped to PMOS as billing systems update, with no patient-facing impact on coverage. If you see PCOS on a chart, a referral, or an insurance form during the transition, that is the system catching up, not an error.
French-language terminology is updating in parallel. Francophone materials are transitioning from syndrome des ovaires polykystiques (SOPK) to SMOP — syndrome métabolique ovarien polyendocrinien — the French equivalent of the PMOS naming, announced alongside the May 2026 Lancet consensus (Vidal). As of mid-2026 the SOPK term remains in active use in Quebec and other francophone settings, and patients should expect a transition period similar to the English one.
For new diagnoses going forward, expect to see PMOS used in newer clinical documents, while older charts, lab reports, and patient education materials will retain the PCOS label for some time. The two refer to the same condition.
What to do if you suspect you have PMOS
Nothing in the diagnostic pathway has changed. The starting point is the same:
- Book a visit with your family physician. Describe the cluster of symptoms — irregular or absent periods, acne or hirsutism, weight gain that resists normal effort, fatigue, mood changes, difficulty getting pregnant if relevant. The pattern matters more than any single symptom.
- Expect a baseline workup. Bloodwork typically includes total and free testosterone, DHEA-S, sex hormone-binding globulin (for a free-androgen-index calculation), TSH, prolactin, fasting glucose or HbA1c, and a lipid panel. Pelvic ultrasound is ordered selectively per the 2023 guideline.
- Confirm against Rotterdam criteria. Two of three features (hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology) after excluding other causes — same as before the rename.
- Build a long-term plan. Lifestyle foundation, cycle and androgen management where appropriate, insulin sensitization where metabolic features dominate, periodic screening for type 2 diabetes and cardiovascular risk factors, and mental-health support as needed.
If you already have a PCOS diagnosis, none of the above is necessary again. Your existing diagnosis stands. The next step is making sure your current management plan reflects the 2023 international guideline — particularly the metabolic and cardiovascular components, which were under-emphasized for years under the old framing and are precisely what the rename is trying to surface.
For the specific case of the abdominal weight pattern many patients with PMOS experience, see our article on PCOS belly fat — the content is fully accurate under PMOS as well. For an overview of how structured clinician-led metabolic care works in Canada, see prescription weight management in Canada. For women using movement as part of their PMOS management, the weighted vest guide for women covers a practical, evidence-backed approach. HSA coverage for structured PCOS/PMOS programs is explained in the Health Spending Account guide.
Start your eligibility check
How Cloudcure approaches PMOS
The rename to PMOS validates the framing Cloudcure's PCOS care program was already built around. The condition has always been metabolic at its core for most patients — the old name just made that harder to talk about. With "metabolic" now in the name itself, the conversation between patients, family physicians, and structured care programs gets meaningfully easier.
Cloudcure's PMOS program is built around the metabolic side of the condition specifically:
- A baseline workup that includes HbA1c, fasting insulin, lipid panel, ALT/AST, and a free-androgen-index calculation where appropriate.
- A 12-month structured arc anchored to the 5–10% sustained weight-reduction target where weight is part of the picture, with monthly clinician follow-up and lab reviews at months 3, 6, and 12.
- Behavioural and nutritional coaching built around the dietary-pattern principles the 2023 international guideline supports.
- Coordination with your family physician, OB-GYN, or endocrinologist — Cloudcure runs the metabolic arc that most primary-care practices do not have the bandwidth to deliver, and refers back where the clinical complexity calls for it.
Membership is $99/month and is HSA- and HCSA-eligible across major Canadian benefits providers.
The PCOS Care program is currently available to Ontario residents. In other provinces, Cloudcure's medical weight-management program supports members managing the condition as part of the broader metabolic picture.
The bottom line on the PMOS rename
Three things worth holding onto:
- It is the same condition. Polyendocrine metabolic ovarian syndrome (PMOS) refers to exactly what polycystic ovary syndrome (PCOS) did. No new tests, no new treatments, no requalification of existing diagnoses.
- The rename clarifies what the condition has always been. Multi-hormone (polyendocrine), insulin-resistance-driven (metabolic), and ovarian-mediated. The old name overweighted the ovarian piece and obscured the rest. The new name corrects that.
- Canadian rollout is in progress. SOGC adoption, provincial billing codes, francophone terminology, and individual physician language are all updating through 2026. Expect a mixed transition period. None of it affects the quality of care you receive.
If you have an existing PCOS diagnosis and want structured metabolic support alongside your existing care team, take Cloudcure's three-minute eligibility check. For some people, the honest answer is that primary care has it covered — and we'll say so.